Aquestive Therapeutics (NASDAQ:AQST) Rating Increased to Hold at Wall Street Zen

Wall Street Zen upgraded shares of Aquestive Therapeutics (NASDAQ:AQST) from a sell rating to a hold rating in a research report released on Saturday,Wall Street Zen reports.

Several other brokerages also recently commented on AQST. Cantor Fitzgerald restated an “overweight” rating and set a $11.00 price objective on shares of Aquestive Therapeutics in a research report on Thursday. Weiss Ratings reiterated a “sell (d-)” rating on shares of Aquestive Therapeutics in a research note on Friday, July 17th. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price target on shares of Aquestive Therapeutics in a research note on Monday, August 24th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Aquestive Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $9.17.

Aquestive Therapeutics Trading Down 4.2%

Aquestive Therapeutics stock opened at $4.78 on Friday. Aquestive Therapeutics has a 12-month low of $2.93 and a 12-month high of $7.55. The firm has a market capitalization of $599.94 million, a price-to-earnings ratio of -7.35 and a beta of 1.48. The firm has a 50 day moving average of $4.39 and a 200 day moving average of $4.26.

Aquestive Therapeutics (NASDAQ:AQST) last issued its quarterly earnings results on Tuesday, August 11th. The company reported ($0.18) earnings per share for the quarter, missing the consensus estimate of ($0.10) by ($0.08). The business had revenue of $13.82 million for the quarter, compared to analyst estimates of $11.42 million. On average, analysts predict that Aquestive Therapeutics will post -0.5 EPS for the current year.

Insiders Place Their Bets

In other Aquestive Therapeutics news, Director Julie Krop sold 25,000 shares of Aquestive Therapeutics stock in a transaction on Tuesday, June 23rd. The shares were sold at an average price of $5.02, for a total value of $125,500.00. Following the sale, the director directly owned 25,000 shares in the company, valued at approximately $125,500. The trade was a 50.00% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Sherry Korczynski sold 8,750 shares of the business’s stock in a transaction on Wednesday, September 9th. The stock was sold at an average price of $5.22, for a total transaction of $45,675.00. Following the completion of the sale, the insider owned 235,689 shares in the company, valued at approximately $1,230,296.58. The trade was a 3.58% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 6.81% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Institutional investors have recently made changes to their positions in the company. NewEdge Advisors LLC purchased a new stake in shares of Aquestive Therapeutics in the third quarter worth about $28,000. BNP Paribas Financial Markets boosted its stake in Aquestive Therapeutics by 78.3% during the second quarter. BNP Paribas Financial Markets now owns 9,413 shares of the company’s stock valued at $31,000 after buying an additional 4,134 shares during the last quarter. ADAR1 Capital Management LLC grew its holdings in Aquestive Therapeutics by 103.9% during the 1st quarter. ADAR1 Capital Management LLC now owns 10,000 shares of the company’s stock valued at $42,000 after buying an additional 264,000 shares in the last quarter. Modern Wealth Management LLC purchased a new position in Aquestive Therapeutics during the 2nd quarter valued at approximately $33,000. Finally, Elevation Point Wealth Partners LLC bought a new stake in Aquestive Therapeutics in the 1st quarter worth approximately $42,000. Hedge funds and other institutional investors own 32.45% of the company’s stock.

About Aquestive Therapeutics

Aquestive Therapeutics, Inc is a specialty pharmaceutical company focused on the development and commercialization of novel drug delivery systems. Leveraging its proprietary PharmFilm® technology, Aquestive designs thin-film formulations that facilitate sublingual, buccal and oral delivery of small molecules, offering rapid onset of action and improved patient compliance compared with traditional dosage forms.

The company’s lead product, Libervant® (diazepam) Buccal Film, is approved by the U.S.